Podcasts about Precision medicine

Teresa Baglietto has lived through the kind of compounded harm that exposes how thin the safety net really is. In this episode she walks through a life shaped by medical neglect, personal violence, and the exhausting labor of self advocacy. She nearly died after a C section when hospital staff failed to confirm she had urinated before discharge, spending 15 days hospitalized and separated from her newborn while facing the possibility of permanent damage. In 2013 she discovered an aggressive breast cancer and waited weeks for test results and surgery while administrators stalled and passed responsibility. Care only moved forward after she threatened public exposure. Teresa also speaks openly about surviving rape in high school, losing her father to cancer at age 48 when she was 10, and growing up without reliable adults in the room. She explains why it took 7 years to write her book, why she launched a podcast, and how sales grit becomes a survival tool when patients must fight systems designed to delay them. The conversation stays specific, unsentimental, and grounded in consequence.RELATED LINKSTeresa Baglietto on LinkedInThe Ripple Effect by Teresa BagliettoIn Shock PodcastIn Shock Podcast on InstagramCanvas Rebel interview with Teresa BagliettoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Science likes to call itself a meritocracy. Angela Anderson and Brandi Mattson know better. Both served as editors at elite journals (Cell and Neuron), where a single decision could determine who gets tenure, funding, or obscurity. They watched brilliant data get filtered out because the authors did not know the unwritten rules controlled by 5 dominant publishing houses with profit margins higher than Google.In 2020, amid pandemic shutdowns and national reckoning over racial injustice, they co-founded a nonprofit to expose that hidden curriculum. Through the JEDI program, they provide 10 hours of free editorial consulting to scientists who lack access to elite networks. In 1 year alone, 25 awards helped researchers salvage canceled grants, secure NSF career funding, and rebuild careers derailed by rejection.This episode pulls back the curtain on the multibillion dollar publishing engine that profits from taxpayer funded science and reveals who gets heard, who gets sidelined, and how insiders are choosing to redistribute power.RELATED LINKSAngela AndersonBrandy MattsonLife Science EditorsLife Science Editors FoundationCellNeuronNational Science FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to PPN – The Precision Medicine Pharmacist, the podcast where science, innovation, and collaboration are redefining patient care. We are kicking off a special two-part series titled Precision Psychiatry in Practice – A Pharmacist–Physician Collaboration. In this series, we explore how precision medicine is reshaping mental health treatment — and what becomes possible when pharmacists and psychiatrists work together with shared clinical goals. Today's episode, The New Frontier: How Pharmacists and Psychiatrists Are Teaming Up for Precision Mental Health, focuses on how this collaboration began — the challenges that inspired it, the early conversations that shaped it, and the practical steps taken to bring pharmacogenomics into psychiatric care. Joining us is Dr. Saba Arshad, clinical pharmacist, founder of Med DNA Health, and a strong advocate for integrating pharmacogenomic insight into mental health treatment. We will also hear from Dr. Afshan Khan, psychiatrist and clinical partner in this model of care, as we explore how their professional paths aligned to create something new. In this first episode, we will lay the foundation — examining the “why” behind precision psychiatry and the systems that had to evolve to support it. Then, in part two, Dr. Khan will join us more extensively as we move from framework to real-world impact, sharing patient cases, clinical outcomes, and lessons learned from implementing precision medicine in practice.

Kristin Ashcraft, Co-Founder and CEO of OncoRx Insights, is determined to bring current information to community-based oncologists to help them identify precision therapies for their patients. The AI platform is designed to augment the oncologist's expertise by analyzing molecular diagnostics, pathology reports, and patient history to identify appropriate FDA-approved drugs and possible clinical trials. The aim is to democratize access to advanced treatment information, bringing the capabilities of academic medical centers to the community setting. Kristin explains, "Our goal is to increase the lifespan of cancer patients by enabling community oncologists to more efficiently identify precision therapies for their patients. We do this through a unique, comprehensive analysis of the molecular diagnostics, patient history, and pathology reports. The reason that we are here is that it can be summed up really well in a study that was recently published in the Journal of Clinical Oncology, in which they found that only 36% of eligible lung cancer patients receive precision medicine therapies. And so OncoRX Insights is focused on bringing greater access to precision medicine for cancer patients."   "Cancer results from genetic mutations from external or inherited causes, and it presents in over a hundred different forms. So as you pointed out, understanding the best possible treatment really is a challenge. But using the molecular diagnostic report and additional information like pathology reports, patient history, understanding those details can really help drive the most targeted treatment to have the best chance of the best outcomes for those patients." #OncoRxInsights #PrecisionMedicine #CancerCare #AIInHealthcare #Oncology #CommunityOncology #HealthTech #MedTech #CancerTreatment #DigitalHealth #PersonalizedMedicine #HealthcareInnovation #CancerResearch #HealthcareInnovation #RealWorldData OncoRxInsights.com Download the transcript here

Kristin Ashcraft, Co-Founder and CEO of OncoRx Insights, is determined to bring current information to community-based oncologists to help them identify precision therapies for their patients. The AI platform is designed to augment the oncologist's expertise by analyzing molecular diagnostics, pathology reports, and patient history to identify appropriate FDA-approved drugs and possible clinical trials. The aim is to democratize access to advanced treatment information, bringing the capabilities of academic medical centers to the community setting. Kristin explains, "Our goal is to increase the lifespan of cancer patients by enabling community oncologists to more efficiently identify precision therapies for their patients. We do this through a unique, comprehensive analysis of the molecular diagnostics, patient history, and pathology reports. The reason that we are here is that it can be summed up really well in a study that was recently published in the Journal of Clinical Oncology, in which they found that only 36% of eligible lung cancer patients receive precision medicine therapies. And so OncoRX Insights is focused on bringing greater access to precision medicine for cancer patients."   "Cancer results from genetic mutations from external or inherited causes, and it presents in over a hundred different forms. So as you pointed out, understanding the best possible treatment really is a challenge. But using the molecular diagnostic report and additional information like pathology reports, patient history, understanding those details can really help drive the most targeted treatment to have the best chance of the best outcomes for those patients." #OncoRxInsights #PrecisionMedicine #CancerCare #AIInHealthcare #Oncology #CommunityOncology #HealthTech #MedTech #CancerTreatment #DigitalHealth #PersonalizedMedicine #HealthcareInnovation #CancerResearch #HealthcareInnovation #RealWorldData OncoRxInsights.com Listen to the podcast here

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Yishan sits down with Dr. Kendall Stewart — a former skull-based surgeon who has spent the past two decades pioneering a data-driven approach to functional medicine, genetics, and neuroimmune health. Together, they explore the biological roots of sleep struggles that behavioral advice alone often can't fix: neurotransmitter imbalances, genetic variants, and inflammation in the nervous system. Dr. Stewart breaks down how genes governing GABA production, melatonin receptor sensitivity, dopamine methylation, and adenosine signaling can silently undermine sleep — and how targeted nutritional support can restore the balance that makes the brain ready for rest.Dr. Stewart also shares remarkable insights from his work with thousands of patients, including children on the autism spectrum, revealing how lessons from neuroimmune research are shaping a new model of precision sleep medicine. He explains why psychological and behavioral sleep therapies work dramatically better when the brain is first supported biologically, and introduces accessible tools — including at-home genetic panels through his company Helix Revolution — that are making personalized care available without a doctor's visit. If you've ever felt that generic sleep advice just doesn't apply to you, this conversation will show you why — and what to do about it.Show Notes: deepintosleep.co/episode/ep209-kendall-stewartRESOURCESAre you so sleepy that you cannot focus? Are you tired of getting through the day drinking coffee? Are you worried how your poor sleep may impact your health? Checkout Dr. Yishan Xu's Insomnia Treatment Course!Connect with Dr. YishanInstagram: @dr.yishanTwitter: @dryishanFacebook: @dr.yishanConnect with Dr. Kendall StewartPodcast: Coffee with Dr. StewartGenetics: Fagron Genetics (formerly GX Sciences)Longevity: ExtendingMeDirect-to-Public Panels: Helix RevolutionNewsletter and Download Free Sleep Guidance E-Book:https://www.mindbodygarden.com/sleepCBT-I Courses:English: https://www.deepintosleep.co/insomniaChinese: https://www.mindbodygarden.com/shimianPodcast Links:Apple Podcast: https://podcasts.apple.com/us/podcast/deep-into-sleep/id1475295840Google Podcast: https://podcasts.google.com/search/deepintosleepStitcher: https://www.stitcher.com/show/deep-into-sleepSpotify: https://open.spotify.com/show/2Vxyyj9Cswuk91OYztzcMSiHeartRadio: https://www.iheart.com/podcast/269-deep-into-sleep-47827108/Support our Podcast: https://www.buymeacoffee.com/dryishanLeave us a Rating: https://podcasts.apple.com/us/podcast/deep-into-sleep/id1475295840If you're interested in learning more about psychological testing and the services offered at the MindBodyGarden make sure to visit their website at mindbodygarden.com/AssessmentClinic.

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Disruption/Interruption, KJ sits down with Oleg Kovalev, Chief Marketing Officer at Aspect Health, revealing how his company became the #1 women's hormonal health startup in the USA by disrupting traditional PCOS treatment. Discover how continuous glucose monitoring and lifestyle coaching are helping one in five women manage a condition that doctors have been treating wrong for decades—and how this medical innovation is driving explosive business growth. Four Key Takeaways: [4:21] PCOS affects 20% of women and is the #1 cause of infertility - Traditional medicine has underdiagnosed and undertreated PCOS for decades, leaving millions of women without proper answers or solutions beyond pills that mask symptoms. [8:33] Managing glucose levels can dramatically reduce PCOS symptoms - Simple lifestyle changes combined with continuous glucose monitoring help women see real-time correlations between their food choices and symptom improvement, leading to exceptional product retention. [17:24] Data-driven positioning beats gut feeling every time - Aspect Health grew 12x in nine months by systematically testing positioning through paid ads and user behavior metrics rather than relying on intuition or assumptions. [24:11] Ask what you should NOT be doing - Focus and intentionality come from eliminating tasks rather than adding them—the critical question every founder and marketer must answer to achieve breakthrough success. Quote of the Show (8:00):"When women go to doctor and they ask questions about PCOS, in most cases they don't get answers to their questions. Often they are given some standard protocol of taking some kind of pills." - Oleg Kovalev Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Oleg Kovalev LinkedIn: https://www.linkedin.com/in/alecko/Company Website: www.aspect-health.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

There is enormous heterogeneity in clinical outcomes and severity of septic shock, with some patients needing only supportive care in the ICU and others progressing to multiorgan system failure and death. How can clinicians identify patients at higher risk of death? In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn Bulloch, PharmD, BCPS, FCCM, is joined by John A. Kellum, MD, FCCM, to discuss high endotoxin activity as a possible endotype for septic shock. Dr. Kellum's article, “Organ Failure, Endotoxin Activity, and Mortality in Septic Shock,” was published in the September 2025 compendium of Critical Care Explorations. Dr. Kellum is a professor and director of the Center for Critical Care Nephrology, as well as vice chair for the Department of Critical Care Medicine, at the University of Pittsburgh in Pittsburgh, Pennsylvania, USA. The study used a novel biomarker called the endotoxin activity assay (EAA) to detect endotoxin in the blood. While the EAA is not good at identifying patients who are at risk for sepsis, Dr. Kellum said that, when combined with organ failure, it identifies patients at high risk for endotoxic septic shock. In the study, these patients had a mortality rate of 60%. Neither the EAA nor the anti-endotoxin therapy is readily available. And, although endotoxic septic shock is rare, occurring in only a quarter of patients with septic shock, Dr. Kellum hopes that, through precision medicine, segmenting this population into treatable subgroups may allow better diagnostics and opportunities to develop or repurpose therapies in the future. This episode is sponsored by Prenosis. Resources referenced in this episode: Organ Failure, Endotoxin Activity, and Mortality in Septic Shock (Molinari  L, et al. Crit Care Explor. 2025;7:e1308) Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis (Seymour CW, et al. JAMA. 2019;321:2003-2017) Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study (TIGRIS) (ClinicalTrials.gov. ID NCT03901807. Last update posted January 9, 2026)

Most doctors treat the average patient. But you are not average, and this episode gives you the precision medicine blueprint to treat yourself like the individual you are, using multi-omic testing, biohacking technology, and longevity science to optimize every layer of your biology. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. Anil Bajnath, a Board-Certified Family Physician, author of The Longevity Equation, and President and Founder of the American Board of Precision Medicine. He serves as Adjunct Professor at the George Washington University School of Medicine and CEO of the Institute for Human Optimization. Dr. Bajnath is certified through the Institute for Functional Medicine, board certified in anti-aging and regenerative medicine, and is one of the few clinicians actively applying genomics, transcriptomics, proteomics, and epigenetics together in a real clinical practice. Together, Dave and Dr. Bajnath break down why population-based medicine fails individuals, how functional medicine and precision science combine to unlock real human performance, and why your mitochondria sit at the foundation of every longevity strategy worth pursuing. They dig into how AI can help you decode your own inflammasome biology, why biohackers are using “sex drugs” to extend longevity, why vagal nerve stimulation directly suppresses the NLRP3 inflammasome, and which biomarkers like MMP9 and homocysteine mainstream medicine keeps ignoring. They also cover peptides, supplements, the dark side of metformin, microdosing for anti-aging, and why biohacking works best when it's personalized and precise. This is essential listening for anyone serious about longevity, smarter not harder health strategies, metabolism, sleep optimization, brain optimization, functional medicine, and taking full control of their biology. You'll Learn: Why precision medicine outperforms population-based health strategies for human performance How to layer genomics, transcriptomics, and proteomics into one complete biological picture Which longevity biomarkers your doctor is likely ignoring, including MMP9 and homocysteine How vagal nerve stimulation suppresses the NLRP3 inflammasome and drives anti-aging benefits The real story on metformin, peptides, and which supplements actually move the needle How AI can help you understand your own biology and act on it faster Why biohacking precision beats random stacking every time Thank you to our sponsors! • Igniton | Head over to Igniton.com and use code DAVE for an exclusive 15% off your first order. • BEYOND Biohacking Conference 2026 | Register with code DAVE300 for $300 off https://beyondconference.com • Caldera + Lab | Go to https://calderalab.com/DAVE and use code DAVE at checkout for 20% off your first order. • Screenfit | Get your at-home eye training program for 40% off using code DAVE at https://www.screenfit.com/dave. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: precision medicine, biohacking, Dave Asprey Cialis, Anil Bajnath, American Board of Precision Medicine, multi-omics, genomics, transcriptomics, proteomics, epigenetics, NLRP3 inflammasome, vagal nerve stimulation, MMP9, homocysteine, mitochondria, longevity, anti-aging, peptides, BPC-157, metformin, rapamycin, functional medicine, human performance, supplements, EGCG, exposome, nitric oxide, vascular health, metabolism, brain optimization, AI health, biohacking technology, Dave Asprey Sex Drugs Resources: • Learn More About Anil's Work And the Institute For Human Optimization At: https://ifho.org/ • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 00:53 – Intro to Precision Medicine 01:58 – Dr. Bajnath's Holistic Health Journey 05:03 – Pharmaceuticals vs. Supplements 07:58 – Peptides and Longevity Molecules 10:34 – Sexual Health and Vitality 13:56 – Vascular Health and Blood Flow 15:14 – Multi-Omics Approach 19:03 – DNA and Genomics 22:17 – Transcriptomics and RNA 24:24 – Proteomics and Inflammation Markers 32:00 – The Human Exposome 34:55 – Key Health Biomarkers 36:58 – Cell Membrane Dynamics 40:28 – Biological Investment Strategy 41:53 – Life Extension Possibilities 48:52 – Bioenergetics and Mitochondria 49:47 – Quantum Medicine and the Future 51:33 – Vagal Nerve Stimulation See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sandeep Palakti spent years at Harvard and Mayo Clinic before realizing the American healthcare system isn't designed to keep people healthy. In this conversation with cardiac surgeon Dr. Philip Ovadia, he breaks down why 70% of physicians are now employed by large health systems or insurers, how that institutional capture prevents real preventative care, and what both doctors and patients can do about it. He explains how he broke free to create Velocity Health, a national concierge practice focused on sleep, diet, exercise, and mental health through precise measurement and individualized strategies. For physicians feeling stuck and patients paying tens of thousands annually for insurance that doesn't deliver health, this conversation maps pathways to better options.BIG IDEAWhen the health insurer owns your doctor, your pharmacy, and your insurance, they have every incentive to drive costs up, reduce quality, and withhold care.Dr. Sandeep “Deep” Palakodeti, MD - Contact InfoBook: The Ultimate AssetWebsite: VelocityHealthClinic.comPodcast: https://velocityhealthclinic.com/the-ultimate-asset-podcast/LinkedIn: https://www.linkedin.com/company/velocityhealth/X: https://x.com/join_velocitySend Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Pre-Order Stay Off My Kitchen Table at Amazon. Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Stay Off My Operating Table on Amazon Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart Health Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some pivotal advancements and strategic shifts within the industry, highlighting how these changes are shaping the future of patient care and drug development.Let's start with Bristol Myers Squibb, which has been making headlines with its latest success in the realm of antibody-drug conjugates (ADCs). The company's ADC has reached an important milestone in a Phase 3 breast cancer trial conducted in China. This study successfully met its dual primary survival endpoints, affirming the company's significant $800 million investment in this promising drug candidate. The potential of ADCs in oncology cannot be overstated; they offer a remarkable combination of targeted therapy by harnessing the specificity of antibodies alongside the cytotoxic power of traditional chemotherapy. This approach not only enhances precision in treatment but also minimizes collateral damage to healthy tissues, showcasing the transformative potential of ADCs in cancer therapy.On the regulatory front, there are ongoing discussions about the impact of political decisions on drug pricing and innovation. The Trump administration's Most Favored Nation drug pricing policy has stirred significant concern within the biotech sector. In response, ten midsize biotech firms have united to form the Midsized Biotech Alliance of America to challenge this policy. They argue that such pricing strategies could hinder innovation by enforcing restrictive pricing models, potentially stalling the development pipeline for new therapies that address unmet medical needs.In terms of strategic corporate movements, Boehringer Ingelheim has entered into a $500 million partnership with a British biotech firm aimed at developing an oral therapy for autoimmune diseases. This collaboration is part of a broader trend towards precision medicine which focuses on modulating specific immune cells to improve treatment outcomes while minimizing unwanted side effects. It's a clear indication that companies are increasingly investing in targeted therapies that promise better efficacy and patient safety. Additionally, Boehringer Ingelheim's partnership with Sitryx underscores another trend: strategic partnerships aimed at innovative research endeavors with substantial investment commitments—potentially exceeding $500 million—to explore immune response modulation.The acquisition landscape is also seeing dynamic shifts. Asahi Kasei's acquisition of Germany's AiCuris for $920 million marks a strategic move to enhance its R&D capabilities, specifically focusing on antiviral therapies for immunocompromised patients. This acquisition aligns with growing global attention towards infectious disease research, especially in a post-pandemic era where preparedness and rapid response capabilities have become paramount.Meanwhile, Sarepta Therapeutics is undergoing a significant leadership change as CEO Doug Ingram announces his retirement. Ingram's leadership was characterized by notable advancements in treatments for Duchenne muscular dystrophy (DMD), although it wasn't without its share of challenges regarding regulatory and pricing debates. As Sarepta continues to expand its gene therapy pipeline, this leadership transition comes at a crucial juncture, potentially setting new directions for the company's future.Accent Therapeutics' recent decision to halt its solid tumor trial due to adverse events exemplifies the risks inherent in drug development. The company is now redirecting its focus towards other cancer programs, illustrating how adaptability remains key in navigating clinical setbacks.Protagonist Therapeutics has made a strategic choice by accepting a $400 million payment from Takeda instead of sharing profits from its hematology asset rusfertide. This decision may provideSupport the show

#403 In this episode, Guy introduced Dr. Lara Varden, a functional genomics practitioner, but the conversation focused largely on her personal healing journey rather than DNA. Dr. Varden described a severe 2001 rear-end collision that left her disabled, in chronic pain, and taking 21–22 prescription medications, leading to multiple spine surgeries and years of impairment. After reading Dolores Cannon's "The Three Waves of Volunteers and the New Earth," she sought a QHHT session in 2015 and says she stopped using her cane immediately and weaned off 14 years of medications within a month, which reframed her approach to integrating science with metaphysical healing. She returned to academia, completed her studies, pursued a funded PhD focused on spine-related research, and later blended holistic, trauma-informed, and energy-based perspectives with scientific genetics and epigenetics. Near the end, they discussed how DNA testing can guide personalized health strategies—especially detoxification and nutrient pathways—shared examples from Guy's genetics, and direct listeners to The DNA Company website, email, and app for reports, education, and testing options. About Dr. Lara: Dr. Lara Varden, Ph.D., is a multi-credentialed clinical practitioner and expert in Precision Medicine. With certifications in functional genomics, nutrition, and holistic health, she has made significant contributions to genetic research and education. In 2024, Dr. Varden helped develop The DNA University, creating training materials to improve patient care globally. Her work spans cellular biology, molecular genetics, and neuroscience, with a focus on empowering people through nutrition and lifestyle changes. As Dean of Students, she emphasizes integrity, proven science, and personalized healing in her practice. Key Points Discussed:  (00:00) - A PhD on 22 Medications Found Dolores Cannon — And Everything Changed! (06:14) - Dr. Lara's Background: From Figure Skater to Scientist (11:38) - The Devastating Car Accident (18:10) - Life on 22 Medications (20:11) - Returning to School Despite Disability (25:11) - The QHHT Session That Changed Everything (27:53) - Miraculous Healing: Off All Medications in One Month (33:48) - PhD Journey: Bridging Science and Spirituality (45:19) - Holistic Healing Philosophy: Root Causes Not Symptoms (57:46) - DNA as Your Body's Blueprint How to Contact Dr. Lara Varden, Ph.D.:thednacompany.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co

In this powerful episode, we sit down with Dr. Joe Zundell — aka “Cancer Daddy” — for a wide-ranging conversation on cancer science, early detection, and what's actually moving the field forward. We cover: • Multi-cancer early detection (MCED) testing and the promise of liquid biopsies • Accuracy, limitations, and clinical decision-making • Metabolic vulnerabilities in cancer (Warburg effect, glutamine dependence) • Epigenetics and tumor biology • Immunotherapy, targeted therapies, and radiopharmaceuticals • Translational research and the bench-to-bedside gap • Drug resistance and evolutionary pressure in cancer treatment • Personalized risk reduction and prevention strategies We also get very personal in this episode — discussing loss, integrity in academia, career pivots, and what truly drives Dr. Zundell's mission in cancer research. This is an honest, science-first, and deeply human conversation about cancer, prevention, innovation, and responsibility in modern medicine. Coach Vinny Email: vinny@balancedbodies.io Instagram: vinnyrusso_balancedbodies Facebook: Vinny Russo Dr. Eryn Email: dr.eryn@balancedbodies.io Instagram: dr.eryn_balancedbodies Facebook: Eryn Stansfield Dr. Joe Zundell Email: drjoezundell@gmail.com Instagram: dr.joezundell LEGION 20% OFF CODE Go to https://legionathletics.com/ and use the code RUSSO for 20% off your order!

In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.   Timestamps:   00:00 – Introduction  02:20 – What drew Anna to haematology  03:57 – Chronic lymphocytic leukaemia  08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia  12:19 – OxPLoreD and STELLAR aims  15:52 – Liquid biopsies  19:56 – Global diagnostics implementation challenges  25:57 – Integrating molecular testing clinically  29:20 – Training future precision leaders  33:51 – Next breakthroughs in precision haematology  35:35 – Three magic wishes 

In today's episode, Lindsey is joined by Dr. Sara Szal Gottfried MD, Director of Precision Medicine at the Marcus Institute of Integrative Health at Thomas Jefferson University, and multiple New York Times bestselling author, to journey into the world of psychedelic medicine and autoimmunity. Morning Microdose is a podcast curated by Krista Williams and Lindsey Simcik, the hosts and founders of Almost 30, a global community, brand, and top rated podcast. With curated clips from the Almost 30 podcast, Morning Mircodose will set the tone for your day, so you can feel inspired through thought provoking conversations…all in digestible episodes that are less than 10 minutes. Wake up with Krista and Lindsey, both literally and spiritually, Monday-Friday. If you enjoyed this conversation, listen to the full episode on Spotify here and on Apple here.

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast was created using NotebookLM.This podcast explores the shift from a one-size-fits-all medical model toward precision medicine, a data-driven strategy that tailors healthcare to an individual's unique genetic and environmental profile.

When Eric Lefkofsky's wife was diagnosed with breast cancer, it exposed how little technology and data were shaping cancer care, pushing the serial entrepreneur to build a different model.Lefkofsky is the founder and CEO of Tempus, now a $10B publicy traded health tech company, and previously founded Groupon. At Tempus, he's building a tech-first company applying multimodal data and AI to make diagnostics smarter and treatment decisions more tailored, starting in oncology and expanding across disease areas.We cover:What Tempus does in plain EnglishWhy Tempus built its own lab, and how it became one of the largest sequencers of cancer patients in the U.S.The hard part: extracting usable clinical data from EHRs and scaling to thousands of hospital connections and hundreds of petabytes of dataHow AI changes the patient-physician relationship, and why patients will increasingly arrive highly informedWhat Eric would change at CMS and HHS to responsibly pay for AI—About our guest: Eric Lefkofsky is the founder and CEO at Tempus, a leader in artificial intelligence and precision medicine. He is the co-founder and General Partner of Lightbank, a private venture capital firm specializing in investments in technology companies. He is also the co-founder of Pathos AI, a clinical stage biotechnology company focused on re-engineering drug development; Groupon (NASDAQ: GRPN), a global e-commerce marketplace; Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics (NASDAQ: ECHO), a technology-enabled transportation and logistics outsourcing firm; and InnerWorkings (NASDAQ: INWK), a global provider of managed print and promotional solutions.He co-chairs the Lefkofsky Family Foundation with his wife Liz to advance high-impact initiatives that enhance lives in the communities served. Lefkofsky also serves on the board of directors of The Art Institute of Chicago and Northwestern Medicine. He holds a bachelor's degree from the University of Michigan and a J.D. from the University of Michigan Law School.—

In this episode of the GSD Presents Silicon Valley AI & Tech series, we sit down with the visionary founders of Matrix Edge Therapeutics, Elaine Phan and Andreas Taylor.We dive deep into how they are building the "Signal → Cure → Longevity" AI infrastructure to revolutionize drug discovery and patient stratification. Learn how continuous patient signals and agentic AI are being used to reduce clinical trial-and-error, speed up cure development, and ultimately extend human healthspan.Key Topics Covered:The shift from reactive medicine to AI-driven Precision Medicine.How "Continuous Patient Signals" improve subtyping and stratification.The role of AI in streamlining the lifecycle from drug discovery to post-market management.The future of longevity and bio-tech innovation.About the Guests:Elaine Phan: Founder of Matrix Edge Therapeutics, Biopharma leader (20+ years), NIH AI strategist, and UC Berkeley/Stanford/Georgia Tech alumna.Andreas Taylor: Co-Founder & CTO, Genentech veteran, Data Scientist, and expert in agentic AI applications and drug delivery.Connect with GSD Venture Studios: gsdvs.com#PrecisionMedicine #AIinHealthcare #Longevity #DrugDiscovery #Biotech #GSDVS #TopGlobalStartups #HealthTech #BioPharma

In this episode of Healthcare Happy Hour, David Saltzman interviews Lena Chaihorsky, co-founder and senior vice president of Payer Innovation at Alva10, discussing the concept of precision medicine and its implications for healthcare delivery. They explore the importance of pharmacogenomics, the role of brokers in implementing precision medicine, and the need for education among employers regarding these innovative healthcare solutions. Lena emphasizes the significance of drug efficacy and the financial implications of non-optimized medications, while also highlighting real-world applications and future directions for the NABIP's Precision Medicine Task Force.

Sunstone Health CEO Joshua Resnikoff joins Chris Lustrino to explain how Sunstone uses AI on healthcare claims data to proactively identify children with developmental delay—starting with epilepsy and autism—and help families reach the right specialists and diagnostics faster.They break down what claims data is, why the healthcare system is reactive by default, and how Sunstone's approach can compress what often takes years into roughly weeks by flagging high-need cases, coordinating advanced diagnostics, and delivering actionable next steps. Joshua also shares Sunstone's go-to-market strategy (positioned as an employer-paid benefit), why the pricing model is designed to reduce “point-solution bloat,” and how expansion could move across employers, TPAs, reinsurers, and large insurers. 00:00 Needle-in-a-haystack intro03:13 What Sunstone does (AI + claims data)05:32 Flagging patients vs. diagnosing07:21 Employer benefit + privacy model15:54 GTM + sales cycle reality17:57 Outcome-based pricing model20:16 Unit economics ($10k per case)22:11 Expansion paths + other diseases26:23 Fundraise use of proceeds28:03 Investor closing

The daughter of a hospital administrator, Amy Gleason never considered a career in the public sector – she went straight into healthcare. As an emergency room nurse, she started to see the dangers that unfold when healthcare providers don't have access to the information they need to treat patients. Those experiences drove her towards a tech career in the emerging electronic health records space before a very personal experience altered her professional path yet again.Amy's active and healthy 10-year old daughter began suffering unusual healthcare events, from rashes and headaches to broken bones. Eventually, she couldn't walk. It took more than a year from the start of these symptoms for doctors to diagnose her with a rare autoimmune disease. Even then, it was an accidental diagnosis from a dermatologist conducting a skin biopsy.Amy attributes the delayed diagnosis to siloed data, not unsimilar to the challenges she experienced as a nurse and was working to solve in the EHR space. It motivated her to co-found a company focused on helping patients with chronic diseases access their data to share it with the providers and family members helping to navigate complex care journeys.In 2015, Amy's work earned her an award from the White House for Champions of Change in Precision Medicine – her first foray into the public sector. By 2018, she entered civic service full time with a role at the United States Digital Service, which she describes as “DOGE 1.0.”In this episode of Healthcare is Hard, Amy talked to Keith Figlioli about the work she's doing now as Strategic Advisor to CMS and Administrator of the U.S. DOGE Service, where her main mission is modernizing technology across government agencies for the millions of people who rely on federal services every day. This ranges from modernizing FAFSA and the student loan process, to improving the Visa system ahead of the World Cup, and work on various critical healthcare systems. Some of the topics Amy and Keith discussed in this episode, include:Bold plans for a Digital Health Ecosystem. Launched in July 2025, CMS' Health Tech Ecosystem is a public-private partnership designed as a voluntary, fast-moving alternative to slow rulemaking. Rather than years of regulation, the program uses pledges, working groups, and short development cycles to put interoperability building blocks and real patient-facing use cases in place. The goal is to get usable capabilities into the market in months – not years – let the community iterate, and have baseline use cases live by March 31, 2026 with more advanced capabilities rolling out by July.Carrots and sticks before regulation. Recognizing the limitations of regulation, Amy talked about a new philosophy for incentivizing the market to change behaviors on its own first. “Carrots” include the rural health transformation fund and the recently introduced ACCESS model, a 10-year pilot that, for the first time, lets tech-enabled services bill Medicare directly. “Sticks” include stricter enforcement of information-blocking rules.Replacing the 1970s-era Medicare claims system. Amy discussed plans to replace Medicare's decades-old COBOL-based adjudication platform. While it's a stable platform, it can't support real-time processing, AI, or rapid change. To replace it, CMS is looking to commercial, off-the-shelf solutions that operate at scale so claims processing can be modernized, made real-time, and integrated with new interoperability rails. It's a concrete example of bringing modern engineering and product thinking to government technology.To hear Amy and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

Dr. Jennifer Perusini, CEO and Founder of Neurovation Labs, is developing a precision medicine platform to create targeted therapeutics and diagnostic tools that treat specific brain regions to address central nervous system diseases. For the treatment of PTSD, the approach focuses on the overactive amygdala due to dysregulated glutamate signaling. This objective, brain-based approach of treating a discrete part of the brain rather than the whole brain moves mental health treatment beyond the current one-size-fits-all approach, reducing side effects and improving outcomes. Jennifer explains, "What we are doing is really taking an objective, precision approach to treating mental health disorders, something like an oncology model. So what we really care about is that mental health disorders and psychiatric disorders are rooted in brain dysfunction, yes, but critically that dysfunction occurs in very discreet brain regions and circuits, not necessarily uniformly across the entire brain. So we have really developed a platform designed to identify compounds with dual potential. Precision therapeutics that act on specific brain regions, as well as diagnostic imaging agents that can reveal receptor-level dysfunction and circuit activity in the brain. And so our lead asset and main indication right now is for PTSD, post-traumatic stress disorder." "I think that academics like to focus on this research in very specific brain regions, but that therapeutic angle really hasn't caught up yet. And so, really more specifically, what we're doing is focusing on a very particular signal, an excitatory neurotransmitter in the brain called glutamate, which is a key regulator of neural activity and cell firing. And so there are many disorders, including PTSD, that are affected by dysregulated glutamate signaling. However, the glutamate drugs that are on the market today really bind to the whole brain. So that's just something that hasn't caught up yet, and that's what we're trying to do." #NeurovationLabs #PrecisionMedicine #PTSD #Neuroscience #MentalHealthInnovation #Biomarkers #DrugDiscovery #Glutamate #BrainHealth #DigitalHealth #HealthTech NeurovationLabs.com Listen to the podcast here

Dr. Jennifer Perusini, CEO and Founder of Neurovation Labs, is developing a precision medicine platform to create targeted therapeutics and diagnostic tools that treat specific brain regions to address central nervous system diseases. For the treatment of PTSD, the approach focuses on the overactive amygdala due to dysregulated glutamate signaling. This objective, brain-based approach of treating a discrete part of the brain rather than the whole brain moves mental health treatment beyond the current one-size-fits-all approach, reducing side effects and improving outcomes. Jennifer explains, "What we are doing is really taking an objective, precision approach to treating mental health disorders, something like an oncology model. So what we really care about is that mental health disorders and psychiatric disorders are rooted in brain dysfunction, yes, but critically that dysfunction occurs in very discreet brain regions and circuits, not necessarily uniformly across the entire brain. So we have really developed a platform designed to identify compounds with dual potential. Precision therapeutics that act on specific brain regions, as well as diagnostic imaging agents that can reveal receptor-level dysfunction and circuit activity in the brain. And so our lead asset and main indication right now is for PTSD, post-traumatic stress disorder." "I think that academics like to focus on this research in very specific brain regions, but that therapeutic angle really hasn't caught up yet. And so, really more specifically, what we're doing is focusing on a very particular signal, an excitatory neurotransmitter in the brain called glutamate, which is a key regulator of neural activity and cell firing. And so there are many disorders, including PTSD, that are affected by dysregulated glutamate signaling. However, the glutamate drugs that are on the market today really bind to the whole brain. So that's just something that hasn't caught up yet, and that's what we're trying to do." #NeurovationLabs #PrecisionMedicine #PTSD #Neuroscience #MentalHealthInnovation #Biomarkers #DrugDiscovery #Glutamate #BrainHealth #DigitalHealth #HealthTech NeurovationLabs.com Download the transcript here

This podcast was created using NotebookLM.This podcast discusses how modern dentistry often relies on a standardized scheduling model that prioritizes production goals over the specific biological and emotional requirements of the individual. 

The data necessary to achieve the promise of precision medicine are now available with low-cost whole-genome sequencing, microbiome analysis, proteomics, and other large datasets. Bioscope has developed a team of AI personas to help clinicians realize that promise in a way that will revolutionize the practice of medicine.In this episode, Sandy Vance speaks with Don Brown, MD, Founder and CEO of Bioscope, about how AI and large-scale biological data are converging to make precision medicine practical for clinicians. They explore Don's entrepreneurial journey, the origins of Bioscope, and how a subscription-based, clinician-first approach is shaping the future of personalized care.In this episode, they talk about:Don Brown's unconventional journey from double-wide to CEO of a groundbreaking companyThe inspiration behind founding Bioscope and the problem it was created to solveHow Don's “entrepreneurial bat signal” attracted talent, partners, and early momentumWhy Bioscope began by partnering with concierge medical practices rather than large health systemsHow Bioscope's per-patient, per-year subscription model works in practiceReal-world use cases and early case studies demonstrating clinical impactWhat the current early rollout looks like and where Bioscope is headed nextA Little About Don:Don Brown, MD, is a serial software entrepreneur, physician, and leader in precision medicine. Over his career, he has founded and scaled multiple groundbreaking technology companies, including Software Artistry, Interactive Intelligence, LifeOmic, and most recently Bioscope.AI. His companies have collectively generated billions in value through public offerings and acquisitions by organizations such as IBM, Genesys, and Fountain Life. In addition to his entrepreneurial work, Don is an active advisor, investor, and philanthropist, including a $30 million gift that established the Brown Immunotherapy Center at Indiana University School of Medicine.Don holds a bachelor's degree in physics and a master's degree in computer science from Indiana University, an MD from Indiana University School of Medicine, and a master's degree in biotechnology from Johns Hopkins University. A lifelong learner, he is fluent in multiple languages, an instrument-rated pilot, an avid outdoorsman, and the author of Understanding Life. He currently serves as Founder and CEO of Bioscope.AI, where he is focused on transforming how clinicians use data to deliver personalized care.

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform. Episode Timestamps;00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma00:19 Meet Michelle Werner: Leading Alltrna's tRNA Platform02:09 From Cancer Clinic to Pharma: A Patient-First Career Path06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style09:37 Vulnerability & Psychological Safety: Building High-Trust Teams11:46 A Personal Turning Point: Her Son's Duchenne Diagnosis17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines33:49 From Preclinical to First-in-Human: Alltrna's 2026 Milestones36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease's Inflection Point? Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options. This episode highlights a pivotal question for the industry:Are rare diseases at the same inflection point oncology experienced two decades ago? Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Michelle Werner;LinkedIn: https://www.linkedin.com/in/michelle-c-werner/Website: https://www.alltrna.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Youngberg introduces a precision medicine approach to Alzheimer's and explains why identifying multiple personal risk factors brings hope for true reversal. #AlzheimersPrevention #PrecisionMedicine #BrainHealth #HealthTalks

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Balancing caregiving and career, Elizabeth Jalazo, M.D. traces how her daughter Evelyn's early feeding challenges and later diagnosis of Angelman syndrome reshape her priorities and professional path. Jalazo describes barriers many families face in rare-disease diagnosis, including a “wait and see” approach, specialist access, and insurance denials, and she emphasizes the value of answers for community, care planning, and research access. At UNC Chapel Hill, Jalazo works as a pediatric geneticist and clinical trialist studying interventional therapies for neurodevelopmental and lysosomal storage disorders, and she serves as chief medical officer of the Angelman Syndrome Foundation. She also leads work on Early Check, an opt-in newborn sequencing program in North Carolina, and shares practical lessons about protecting sleep, building support, and saying no while holding space for hope and joy Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 41173]

Balancing caregiving and career, Elizabeth Jalazo, M.D. traces how her daughter Evelyn's early feeding challenges and later diagnosis of Angelman syndrome reshape her priorities and professional path. Jalazo describes barriers many families face in rare-disease diagnosis, including a “wait and see” approach, specialist access, and insurance denials, and she emphasizes the value of answers for community, care planning, and research access. At UNC Chapel Hill, Jalazo works as a pediatric geneticist and clinical trialist studying interventional therapies for neurodevelopmental and lysosomal storage disorders, and she serves as chief medical officer of the Angelman Syndrome Foundation. She also leads work on Early Check, an opt-in newborn sequencing program in North Carolina, and shares practical lessons about protecting sleep, building support, and saying no while holding space for hope and joy Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 41173]

Balancing caregiving and career, Elizabeth Jalazo, M.D. traces how her daughter Evelyn's early feeding challenges and later diagnosis of Angelman syndrome reshape her priorities and professional path. Jalazo describes barriers many families face in rare-disease diagnosis, including a “wait and see” approach, specialist access, and insurance denials, and she emphasizes the value of answers for community, care planning, and research access. At UNC Chapel Hill, Jalazo works as a pediatric geneticist and clinical trialist studying interventional therapies for neurodevelopmental and lysosomal storage disorders, and she serves as chief medical officer of the Angelman Syndrome Foundation. She also leads work on Early Check, an opt-in newborn sequencing program in North Carolina, and shares practical lessons about protecting sleep, building support, and saying no while holding space for hope and joy Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 41173]

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In Part 1 of this conversation, Jamie sits down with nurse practitioner Jaclyn Taylor to pull wellness out of the “buzzword” category and into real life. They talk about why so many people feel stuck—fatigued, anxious, gaining weight, losing motivation—and why the first step isn't a perfect plan…it's being listened to. Jaclyn breaks down what the Your Health Wellness Program offers, how bioidentical hormone replacement therapy works, and why “normal labs” don't always mean you're actually okay. This episode is for anyone who's been powering through, silently struggling, or wondering if feeling better is still possible. www.YourHealth.Org

In this episode, Dr. Greg Jones sits down with Dr. Sharon Hausman-Cohen, Chief Medical Officer of IntelliXX DNA, to explore how medical genomics is transforming the way we understand heart disease, brain health, inflammation, and metabolism. Most people think genetics stops at traits like eye color or ancestry. Genomics goes much deeper—analyzing how thousands of genes interact to influence cardiovascular risk, cognitive function, clotting tendencies, nutrient metabolism, and chronic inflammation.Dr. Hausman-Cohen explains why many direct-to-consumer DNA tests fall short, how incomplete interpretation can mislead patients, and why clinician-guided genomic analysis allows for truly personalized care. The conversation also dives into inflammation, methylation, homocysteine, cholesterol myths, caffeine metabolism, mitochondrial health, and women's unique clotting risks.Whether you're trying to reduce your risk of heart disease, improve mental clarity, or understand how your biology responds to diet, supplements, and medications—this episode offers a science-based roadmap for precision health.

This podcast was created using NotebookLM.This podcast discusses how precision medicine uses genomics, AI, and salivary biomarkers to provide personalized dental care for older adults with multimorbidity. 

Today, I have the privilege of connecting with Dr. Sara Gottfried! Dr. Sara is a board-certified physician who graduated from Harvard and MIT. She practices evidence-based, integrative, precision, and functional medicine. She is a Clinical Assistant Professor in the Department of Integrative Medicine and Nutritional Sciences at Thomas Jefferson University and Director of Precision Medicine at the Marcus Institute of Integrative Health. She has written four New York Times bestselling books, including her latest, Women, Food and Hormones.  Dr. Sara is one of my favorite doctors in integrative medicine and GYN! In this episode, we dive into the infodemic, how stress impacts hormones, the impact of age-related changes on hormonal regulation, alcohol, and gender differences with ketogenic lifestyles. We discuss some lesser-known hormones, including growth hormone, and how to support them properly. We touch on disordered eating, how trauma influences our relationship with food, epigenetics, and the role of a lifetime relationship with food. We also look at methylation, glutathione, detox reactions, supporting physical detoxification, and our toxic diet culture. I hope you benefit as much from this episode as I did!  IN THIS EPISODE YOU WILL LEARN: Dr. Sara explains what an infodemic is and how it has affected how she communicates with her patients.  What happens to our hormones as we age? The impact of stress on hormone regulation. Dr. Sara busts the myth that testosterone is a male hormone and discusses what testosterone means for women. How does alcohol consumption impact women's hormones? Why do men tend to have an easier time with the ketogenic diet than women? The dramatic changes that occur in women's bodies as they transition from perimenopause to menopause. Looking at the interrelationship between trauma, stress, and autoimmunity. The changes that occur with growth hormones as we age. How trauma affects the genes. How disordered eating impacts metabolism. How to support physical detoxification naturally, without going to extremes. How to address weight-loss plateaus. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community (The Midlife Pause/Cynthia Thurlow)  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause supplement line Connect with Dr. Sara Gottfried On her ⁠website⁠ ⁠Facebook⁠, ⁠Instagram⁠ Dr. Sara's books are available on https://www.saragottfriedmd.com/ and ⁠Amazon.⁠

Why do so many people feel unwell even when their labs are labeled "normal"? Are we using laboratory testing as a guide, or are we letting numbers drive decisions without enough context? In this episode, I sit down with Dr. Ralph Esposito, a board-certified nutritionist, functional medicine practitioner, and expert in metabolic health, to unpack one of the most misunderstood tools in modern medicine: laboratory testing. As Dr. Esposito explains, labs are a cornerstone of healthcare, but they are also among the most frequently misused. We explore how nutrition and metabolic labs should be evaluated responsibly by prioritizing clinical context, pre-test probability, biological variability, and individual response rather than relying on isolated or outdated reference ranges. Our conversation also dives into common misunderstandings around testosterone replacement therapy, cardiovascular risk, and why population-based "normal" values often miss what is happening in the individual. Dr. Esposito introduces an N of 1 framework, reframing labs not as definitive answers but as decision-support tools meant to guide truly personalized care. If you want a clearer, more thoughtful way to interpret labs and assess real health risk, this episode will change how you look at your numbers.   Key takeaways: Lab Interpretation Caution: Misinterpretation of lab results can lead to incorrect health assessments; patient history and context are crucial in lab result analysis. Individualized Guidelines: Dr. Esposito advocates for a shift from population-based to personalized markers of health for more accurate patient care. Role of Testosterone in Health: While TRT can be beneficial, it should be considered carefully, weighing potential health benefits against side effects like elevated hematocrit and hemoglobin levels. Lifestyle Modifications: Recognize the impact of lifestyle changes in conjunction with medical treatments for long-term health improvements. Precision Medicine Vision: The future of healthcare lies in the integration of AI and individualized patient data to tailor precise medical interventions effectively.   More About Dr. Ralph Esposito:   Dr. Ralph Esposito is a licensed naturopathic physician and acupuncturist specializing in precision preventive and integrative medicine. He serves as Chief Science Officer at AG1 where he oversees scientific strategy and clinical research and is an adjunct professor at New York University. His work focuses on evidence-based N-of-1 approaches to risk reduction metabolic health and longevity translating complex science into clinically meaningful outcomes.   Website Instagram Connect with me! Website Instagram Facebook YouTube

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The most effective way to drive change in healthcare is to focus on what remains constant: serving patients. In this episode, sponsored by Amgen. Leandro Boer, Vice President of US Medical and General Medicines at Amgen, discusses how the company is reimagining care delivery to enhance access and outcomes, particularly for underserved populations. He explains how precision medicine, multi-omics, and advanced data use are driving innovation and preventing “data waste,” while Amgen invests heavily in R&D, including a $600 million Innovation and Discovery Science Center. Leandro highlights the role of technology in accelerating clinical trials through machine learning and anticipates three major shifts within the next five years: faster drug development, reduced administrative burden through the use of AI, and improved patient identification via care pathway automation. He also highlights Amgen's goal to reduce cardiovascular events by 50% by 2030, the importance of diverse clinical representation through the RISE initiative, and the company's commitment to employee well-being as the foundation for improved patient care. Tune in and learn how innovation, equity, and purpose-driven leadership are transforming the future of healthcare! Resources: Connect with and follow Leandro Boer on LinkedIn. Follow Amgen on LinkedIn and explore their website.

Is modern medicine still evidence-based, or have we quietly mistaken rigor for certainty?Evidence-based medicine is essential. It's why we save lives, advance care, and trust modern healthcare. But as medicine has become more specialized and disease more complex, something subtle has happened. Rigor has increasingly turned into reductionism, and evidence is often applied in ways that don't fully match the realities of clinical practice or patients' lived experiences.In this episode of The Trip Lab, I take a careful look at what we mean when we say “evidence-based medicine.” We explore the difference between statistical significance and clinical significance, how guidelines are created and why they are evidence-informed rather than infallible, and why many patients feel unwell despite having “normal” labs.This conversation also examines how modern research methods struggle to capture complexity, particularly in chronic, system-level disease. We look at where reductionism has helped medicine advance, where it now falls short, and why ancient healing systems and emerging fields like systems biology, functional medicine, and precision medicine are pointing us toward a more integrated future.This episode is not a rejection of evidence. It's an invitation to reclaim it. To restore clinical wisdom alongside data, and to practice medicine with both rigor and curiosity.In this episode, we cover:What “evidence-based medicine” actually means and how it's evolvedStatistical significance vs. clinical significanceThe strengths and limitations of medical guidelinesWhy reductionist models don't fully explain chronic diseaseWhy patients can feel unwell even when labs are “normal”How medicine might evolve to better study complexityWhy medicine is both a science and an artThe podcast name, The Trip Lab, nods to psychedelics, but a “trip,” psychedelic or otherwise, is ultimately an exploration. A willingness to step outside familiar frameworks, question what we think we know, and notice connections that weren't obvious before.If you've ever felt tension between what the data says, what the guidelines allow, and what the patient in front of you actually needs... or if you are a patient who has been failed by modern medicine, this episode is for you.

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma. --- SYNPOSIS The doctors examine the evolving management of muscle-invasive bladder cancer (MIBC), including the role of neoadjuvant and adjuvant therapies, the integration of immunotherapy, and the recent approval of enfortumab vedotin plus pembrolizumab. The discussion explores the rapidly changing perioperative landscape, the prognostic utility of ctDNA, and how biomarkers such as HER2 and FGFR are influencing treatment selection across disease states. They also address bladder preservation strategies, management of treatment-related toxicities, and the importance of multidisciplinary coordination. The episode concludes with a forward-looking discussion on emerging therapies and the potential to improve cure rates in bladder cancer. --- TIMESTAMPS 00:00 - Introduction01:44 - Overview of Bladder Cancer Treatment04:54 - Patient Staging and Treatment Goals10:12 - Bladder Preservation vs. Radical Cystectomy16:39 - Emerging Trials and Future Directions22:40 - ctDNA and Precision Medicine33:50 - Metastatic Disease and Biomarker Strategies42:16 - Managing Neuropathy in Metastatic Treatment48:44 - HER2 and FGFR in Bladder Cancer54:15 - Future Directions in Bladder Cancer Treatment --- RESOURCES EV-302/303 Trialhttps://newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedotin-ejfv-with-KEYTRUDA-R-pembrolizumab-Approved-by-FDA-as-the-First-and-Only-ADC-Plus-PD-1-to-Treat-Advanced-Bladder-Cancer NIAGARA Regimenhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408154 KEYNOTE-905 Studyhttps://www.annalsofoncology.org/article/S0923-7534(25)04894-X/fulltext

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Eye on AI Podcast, Craig Smith sits down with Steve Brown, founder of CureWise, to explore how agentic AI is reshaping healthcare from the patient's perspective. Steve shares the deeply personal story behind CureWise, born out of his own experience with a rare cancer diagnosis that was repeatedly missed by traditional medical pathways. The conversation dives into why modern healthcare struggles with complex, edge-case conditions, how fragmented medical data and time-constrained systems fail patients, and where AI can meaningfully help without replacing clinicians. The discussion goes deep into multi-agent AI systems, reliability through consensus, large context windows, and how AI can surface better questions rather than premature answers. Steve explains why patient education is the real unlock for better outcomes, how precision medicine depends on individualized data and genetics, and why empowering patients leads to stronger collaboration with doctors. This episode offers a grounded, practical look at AI's role in healthcare, not as a diagnostic shortcut, but as a tool for clarity, context, and better decision-making in some of the most critical moments of car   Stay Updated: Craig Smith on X: https://x.com/craigssEye on A.I. on X: https://x.com/EyeOn_AI (00:00) Using Multi-Agent AI to Analyze Medical Records (04:35) Steve Brown's Tech Background and Return to Healthcare (08:25) How a Rare Cancer Diagnosis Was Initially Missed (13:55) Why Modern Medicine Struggles With Complex Cases (18:29) Multi-Agent Consensus and AI Reliability in Healthcare (24:12) Large Context Windows, RAG, and Medical Data Organization (28:24) Why CureWise Focuses on Patient Education, Not Diagnosis (33:10) Precision Medicine, Genetics, and Personalized Treatment (47:45) Why CureWise Launches Direct-to-Patient First (53:19) The Future of AI-Driven Precision Medicine

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.